AstraZeneca, like the rest of the pharmaceuticals space, has been fighting an intense rearguard action in recent years on the revenues front. This has been prompted by a steady increase in patent expirations across sales-critical drugs, such as its Crestor and Nexium labels, products which account for 35% of group revenues alone.